claudiowall
Short

#Nasdaq #Biotech It ought to correct overbought

INDEX:NBI   Nasdaq Biotechnology Index
It ought to correct overbought Nasdaq Biotechnology Index:
The Nasdaq Biotech index             has grown about 50 percent since Yellen's valuation comments. Superarando por mucho el desempeño de los indices composite y S&P500             , this boom is due primarily to the pharmaceutical companies who have monopolized the attention of investors the past few months, beyond the debate of whether exist a bubble formation the Nasdaq Biotechnology Index             It ought to correct their overbought at least 6% as it has done in later months

http://www.bloomberg.com/news/articles/2015-03-20/biotech-has-surged-massively-since-warning-from-the-fed
snapshot


Article:
Biotechs could be the early warning for stocks http://cnb.cx/1N9Sg68

The uncertainty caused by the excessive increase in the valuation of shares, based on the promises of extraordinary cash flows through products that are still in experimental stages of research and development is an increasingly risky. The appetite for higher-yielding assets and high risk is associated with the availability of liquidity injected by central banks in the market at low interest rates, when a change occurs in this scenario the liquidation of long positions will result in a significant correction that all expect.
Reply
United States
United Kingdom
India
Deutschland
España
France
Italia
Polska
Brasil
Россия
Türkiye
Indonesia
Malaysia
日本
한국
Home Stock Screener Forex Signal Finder Economic Calendar How It Works Chart Features House Rules Moderators For the WEB Widgets Stock Charting Library Priority Support Feature Request Blog & News FAQ Help & Wiki Twitter
Profile Profile Settings Account and Billing Priority Support Ideas Published Followers Following Private Messages Chat Sign Out